

## Referenser till kapitel Psykiatri:

1. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). *The Lancet*. 2009 Aug;374(9690):620–7.
2. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *The Lancet*. 2013 Sep;382(9896):951–62.
3. Does clozapine have a protective effect for suicide in people with schizophrenia or schizoaffective disorder? [Internet]. SMI Adviser. 2023. Available from: [https://smiadviser.org/knowledge\\_post/does-clozapine-have-a-protective-effect-for-suicide-in-people-with-schizophrenia-or-schizoaffective-disorder](https://smiadviser.org/knowledge_post/does-clozapine-have-a-protective-effect-for-suicide-in-people-with-schizophrenia-or-schizoaffective-disorder)
4. Meltzer HY. Clozapine Treatment for Suicidality in Schizophrenia International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry*. 2003 Jan 1;60(1):82.
5. Wong J, Pang T, Cheuk NKW, Liao Y, Bastiampillai T, Chan SKW. A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders. *Psychopharmacology (Berl)*. 2022 Nov;239(11):3393–420.
6. Oloyede E, Blackman G, Whiskey E, Bachmann C, Dzahini O, Shergill S, et al. Clozapine haematological monitoring for neutropenia: a global perspective. *Epidemiol Psychiatr Sci*. 2022;31:e83.
7. De las Cuevas C, Sanz EJ, Ruan CJ, de Leon J. Clozapine-associated myocarditis in the World Health Organization’s pharmacovigilance database: Focus on reports from various countries. *Rev Psiquiatr Salud Ment*. 2022 Oct;15(4):238–50.
8. Leung JG, de Leon J, Frye MA, Singh B, Cotes RO, McElroy SL. The Modernization of Clozapine: A Recapitulation of the Past in the United States and the View Forward. *J Clin Psychopharmacol*. 2022 Nov;42(6):565–80.
9. Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, et al. The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption: A Randomized, Open-Label, Crossover Trial. *J Clin Psychiatry*. 2009 Jan 15;70(1):58–62.
10. Preskorn S, Ereshefsky L, Chiu YY, Poola N, Loebel A. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies: EFFECT OF FOOD ON LURASIDONE PHARMACOKINETICS. *Hum Psychopharmacol Clin Exp*. 2013 Sep;28(5):495–505.
11. Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJP, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? *Aliment Pharmacol Ther*. 2005 Aug;22(3):175–81.
12. de Abajo FJ, García-Rodríguez LA. Risk of Upper Gastrointestinal Tract Bleeding Associated With Selective Serotonin Reuptake Inhibitors and Venlafaxine Therapy: Interaction With Nonsteroidal

Anti-inflammatory Drugs and Effect of Acid-Suppressing Agents. *Arch Gen Psychiatry*. 2008 Jul 7;65(7):795.

13. Henssler J, Alexander D, Schwarzer G, Bschor T, Baethge C. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2022 Apr 1;79(4):300.
14. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*. 2018 Apr;391(10128):1357–66.
15. Finch CK, WA Brooks T, Yam P, Kelley KW. Management and treatment of lithium-induced nephrogenic diabetes insipidus. *Therapy*. 2005 Jul;2(4):669–75.
16. Bedford JJ, Weggerly S, Ellis G, McDonald FJ, Joyce PR, Leader JP, et al. Lithium-induced Nephrogenic Diabetes Insipidus: Renal Effects of Amiloride. *Clin J Am Soc Nephrol*. 2008 Sep;3(5):1324–31.
17. Batlle DC, von Rott AB, Gaviria M, Grupp M. Amelioration of Polyuria by Amiloride in Patients Receiving Long-Term Lithium Therapy. *N Engl J Med*. 1985 Feb 14;312(7):408–14.
18. Boaden K, Tomlinson A, Cortese S, Cipriani A. Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment. *Front Psychiatry*. 2020;11:717.
19. Courtney RJ, McRobbie H, Tutka P, Weaver NA, Petrie D, Mendelsohn CP, et al. Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial. *JAMA*. 2021 Jul 6;326(1):56–64.
20. Walker N, Smith B, Barnes J, Verbiest M, Parag V, Pokhrel S, et al. Cytisine versus varenicline for smoking cessation in New Zealand indigenous Māori: a randomized controlled trial. *Addiction*. 2021 Oct;116(10):2847–58.
21. Luft MJ, Lamy M, DelBello MP, McNamara RK, Strawn JR. Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management. *Curr Probl Pediatr Adolesc Health Care*. 2018 Feb;48(2):50–62.
22. Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. *World Psychiatry*. 2020 Jun;19(2):214–32.
23. Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. *Br J Psychiatry*. 2011 Oct;199(4):281–8.
24. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al. Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. *Am J Psychiatry*. 2008 Nov;165(11):1420–31.

25. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. *Curr Opin Psychiatry*. 2013 Mar;26(2):219–30.